Merck looks to ditch the needles with its next-gen oral PCSK9 inhibitor for high cholesterol
After winning approval about six years ago, the first wave of PCSK9 inhibitors largely failed to muster the blockbuster sales analysts had predicted. Now Merck is hoping its oral option will find better success.
The pharma giant unveiled on Monday what it says are the first in-human results for an oral PCSK9 inhibitor. The candidate, MK-0616, was well-tolerated in men and women with high cholesterol at doses up to 300 mg, with no deaths or serious side effects, the company said at the American Heart Association conference.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
